Efficacy of Retreatments With Intravitreal Bevacizumab

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2006 by Asociación para Evitar la Ceguera en México.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:
NCT00406744
First received: November 30, 2006
Last updated: NA
Last verified: November 2006
History: No changes posted

November 30, 2006
November 30, 2006
May 2006
Not Provided
Best corrected visual acuity, OCT foveal thickness and fluorescein angiogram
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Efficacy of Retreatments With Intravitreal Bevacizumab
Evaluation of Efficacy of Intravitreal Bevacizumab Retreatments

Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Age Related Macular Degeneration
  • Choroidal Neovascularization
Drug: Intravitreal injection of Bevacizumab
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
November 2006
Not Provided

Inclusion Criteria:

  • * Any visual acuity

    • OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid.
    • Active angiogram leakage

Exclusion Criteria:

  • * Basal Inflammatory disease

    • Endoftalmitis history
    • Lesions bigger than 5400 u or with scarring greater than 50% of lesion.
Both
60 Years to 95 Years
No
Contact: Veronica A Kon-Jara, MD 525510841400 ext 1172 veronicakon@yahoo.com
Contact: Hugo Quiroz-Mercado, MD 525510841400 ext 1171 retinamex@yahoo.com
Mexico
 
NCT00406744
APEC-0012
Not Provided
Not Provided
Asociación para Evitar la Ceguera en México
Not Provided
Principal Investigator: Veronica Kon-Jara, MD APEC
Asociación para Evitar la Ceguera en México
November 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP